Innovation in pain relief

Lacking of sufficient treatments

PharmNovo AB is a clinical-phase pharmaceutical company focused on developing safe and effective drugs for neuropathic pain.

Neuropathic pain affects up to ten percent of the population in Europe and the United States, and there is a lack of sufficient treatment. Existing chronic pain drugs are only partly effective and only for some patients, and they are associated with significant side effects.

PharmNovo’s mission is to develop safe and effective treatments for neuropathic pain to accomplish our vision to change the lives of people suffering from this condition.

The company's drug candidate, PN6047, about to enter phase II proof-of-concept studies, has effectively reduced neuropathic pain in preclinical studies. The primary indication is neuropathic pain with allodynia, which is a condition where, for example, light touch triggers severe pain. PharmNovo also sees clinical potential for the drug in other areas, such as migraine, anxiety/depression, and chronic cough.

Latest news

View all

July 8, 2025

Breaking new ground in pain management

Breaking new ground in pain management In the latest episode of BioBizBuzz, PharmNovo CEO Per von Mentzer sits down with host Mike Ward to discuss how we’re tackling one of modern medicine’s most urgent challenges: finding effective, non-addictive treatments for chronic and neuropathic pain. The conversation highlights the development of our lead candidate PN6047, a selective delta-opioid receptor agonist designed to deliver strong pain relief without the addiction risks or sedation associated with traditional opioids. Per shares insights into the scientific rationale, clinical potential, and why neuropathic pain—often caused by nerve damage from conditions like diabetes or chemotherapy—demands new thinking. For anyone interested in neuroscience, biotech innovation, or the future of pain management, this episode offers a glimpse into what could become a paradigm shift in treatment. Listen to the full episode here:

July 1, 2025

CTA submission for PN6047

PharmNovo AB is pleased to announce that the clinical trial application (CTA) for a Phase IIa proof of concept (PoC) study investigating the safety and efficacy of lead candidate PN6047 in patients with neuropathic pain has been submitted in Spain. The full title of the application is: “Randomized Double-Blind Placebo-Controlled Cross-Over Trial of the Safety, Tolerability, and Efficacy of PN6047 HCl in Peripheral Neuropathic Pain Characterized by Mechanical Allodynia.” Based on a strategic company decision, PharmNovo has submitted the CTA, in the first instance, to the Spanish Health Authorities only. Submission to the Czech Republic and Poland, the two other countries in which the trial will be conducted, is planned to take place following approval in Spain, which is expected by October 2025. Subject to additional investment, patient enrolment is expected to start by Quarter 1 2026.

PharmNovo at the LSX World Congress in London

May 19, 2025

PharmNovo at the LSX World Congress in London

Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Congress in April 2025 in London. PharmNovo is redefining pain management with PN6047, a first-in-class Delta Opioid Receptor Agonist (DORA), safer, non-addictive solution for neuropathic pain. Unlike traditional opioids, PN6047 eliminates concerns of side effects, abuse potential, and tolerance. With a proven safety profile from Phase I trials and a market projected to exceed EUR 13 billion by 2033, PN6047 is set to be a game-changer.

March 12, 2025

Positive FDA feedback for PN6047

PharmNovo has received positive and constructive feedback from the FDA for its lead drug candidate, PN6047, a selective delta opioid receptor agonist aimed at treating peripheral neuropathy with allodynia. Following a successful pre-IND meeting in January 2025, the FDA provided valuable guidance on the Phase IIa study design and had no critical comments on the CMC or non-clinical data. This paves the way for IND submission by the end of 2025 and a Phase IIa clinical trial application in Europe (Spain, Poland, Czech Republic) by Q3 2025.